Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 539523 | NSE Symbol : ALKEM | ISIN : INE540L01014 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
28-Jan-2025	07-Feb-2025	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve (i) the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2024; and (ii) Interim Dividend for financial year 2024-2025. The record date for the purpose of payment of Interim Dividend for financial year 2024-2025 would be Friday 14th February 2025 subject to declaration of the said Interim Dividend by the Board of Directors in its meeting to be held on 07th February 2025. Please find enclosed herewith the Outcome of the Board Meeting dated 7th February, 2025. The meeting of the Board of Directors of the Company commenced at 11.00 am and concluded at 13.40 pm. Kindly take the same on record. (As Per Bse Announcement Dated on 07.02.2025)
05-Nov-2024	13-Nov-2024	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve The Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2024. Please find enclosed herewith the outcome of the Board meeting dated 13th Nov, 24. (As Per BSE Announcement Dated on 13.11.2024)
25-Jul-2024	09-Aug-2024	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June 2024. Please find enclosed the outcome of BM dated 9th Aug 24 The BOD at its meeting held today 9th Aug 24 approved the appt of Mr. Rajeev Kher as an additional director designated as an Independent Director on the BOD of the Company for a period of 5 consecutive years w.e.f 9th Aug, 2024 upto 8th Aug, 2024 subject to approval of shareholders of the Company (As Per BSE Announcement dated on 09.08.2024)
16-May-2024	29-May-2024	Accounts	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve Alkem Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve (i) the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March 2024; and (ii) to consider and recommend Final Dividend if any for financial year ended 31st March 2024. Kindly take note of the same. The BOD at its meeting held today 29.5.24 has recommended final dividend of Rs. 5 per equity share of Rs. 2 each for FY 31st march 24 for approval of shareholders in the ensuing AGM Please find enclosed herewith the outcome of the Board meeting dated 29th May, 2024 Enclosed herewith are the details of the re-appointment of certain Directors of the Company. Pl. find enclosed Audited Financial results for quarter and year ended 31st march 24 Enclosed herewith are the details of appointment of M/s Deloitte Haskins & Sells LLP, Chartered Accountants as the Statutory Auditors of the Company. (As Per BSE Announcement dated on 29.05.2024)
01-Feb-2024	09-Feb-2024	Interim Dividend	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2024 inter alia to consider and approve (i) the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2023; and (ii) Interim Dividend for financial year 2023-2024. The record date for the purpose of payment of Interim Dividend for financial year 2023-2024 would be Saturday 17th February 2024 subject to declaration of the said Interim Dividend by the Board of Directors in its meeting to be held on 09th February 2024. Interim dividend declared of Rs. 35 per share and pay out on and from 1st March The Company has fixed 23rd Feb as cut off date. (As Per BSE Announcement dated on 09.02.2024)
27-Oct-2023	07-Nov-2023	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2023. Kindly take note of the same. The Board of Directors at its meeting held today i.e. 07th November, 2023, has, inter alia: 1. approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2023. 2. approved the amendment to object clause of the Memorandum of Association of the Company by inserting certain new object clauses after sub clause 2 of Clause III(A) - Main Objects ('The objects to be pursued by the Company on its incorporation'), subject to approval of shareholders of the Company through Postal Ballot. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023. A copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is also enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 1.40 p.m. Please find attached herewith copy of unaudited financial results and limited review of the Statutory Auditors is enclosed herewith The BoD at its meeting today approved the amendment to the object clause of MOA by inserting certain new object clauses after sub clause 2 in clause III(A) - Main objects for widening the scope of activities to be carried out by the Company under ambit of healthcare business, subject to approval of shareholders by way of Postal Ballot The BOD have approved the amendment to the objects of MOA in its meeting held today. (As Per BSE Announcement Dated on 07.11.2023)
31-Jul-2023	10-Aug-2023	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June 2023. Kindly take note of the same. The Board of Directors of the Company, at its meeting held today, i.e. 10.08.2023 have approved the Standalone and Consolidated Unaudited Financial Results for the QE 30.06 2023. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Reg 33 of the Listing Regulations, is enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.45 A.M and concluded at 1.45 P.M. Kindly take the same on record. Kindly refer to our intimation letter dated 31st July 23 pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (LODR) Reg, 2015. We are enclosing the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June 23 duly approved by the BOD of the Company at its meeting held today i.e 10th Aug, 23. A copy of the Unaudited Financial Results and Limited Review Report is enclosed herewith. The meeting of BOD commenced at 11.45 and concluded at 1.45 pm. This is to inform you that pursuant to the provisions of Sec 110 and other applicable provisions of the Companies Act 2013 read with Rule 20 as and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors of the Company at its meeting held today 10th Aug 23 have decided to seek approval of shareholders by way of Postal Ballot (voting through electronic means) for appointment of Mr.Aniruddha Singh , son of Mrs. Madhurima Singh, Executive Director of the Company to hold office of profit as AVP- CMD office of the Company w.e.f 23rd Nov, 23. The Company has fixed 1st Sept, 23 as the cut off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and voting through electronic means. (As Per BSE Announcement dated on 10.08.2023)
09-May-2023	19-May-2023	Accounts	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2023 inter alia to consider and approve (i) the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March 2023; and (ii) to consider and recommend Final Dividend if any for financial year ended 31st March 2023. Kindly take note of the same. The Board of Directors at its meeting held today i.e. 19th May, 2023, has, inter alia: 1. recommended a final dividend of Rs. 10/- (Rupees Ten only) per equity share of Rs. 2/- each for the financial year ended 31st March, 2023, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 49th Annual General Meeting of the Company shall be held on 25th August, 2023 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2023. 3. fixed 10th August, 2023 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2023. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 1.30 p.m. Kindly take the same on record. The Board of Directors at its meeting held today i.e. 19/05/2023, has, inter alia: 1. approved the Standalone and Consolidated Audited Financial Statements of the Company for the quarter and FY ended 31/03/2023. 2. recommended a final dividend of Rs. 10/- per equity share of Rs. 2/- each for FY ended 31/03/2023, for the approval of the shareholders of the Company at the ensuing AGM. 3. fixed that the 49th AGM of the Company shall be held on 25/08/2023 and the cut-off date for the purpose of the said AGM has been fixed as 18/08/2023. 4. fixed 10/08/2023 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30/08/2023. 5. Approved the alteration of AOA of the Company, subject to the approval of the shareholders at the ensuing AGM of the Company. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 1.30 p.m. In continuation of our letter dated 9th May, 2023 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR Regulations, the Board of Directors of the Company, at its meeting held today, i.e. 19th May, 2023, has inter alia approved the Standalone and Consolidated Audited Financial Statements for the quarter and financial year ended 31st March, 2023. The Company hereby declares that the Auditors have expressed an unmodified opinion in the Audit Reports on Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2023. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.30 P.M. The Board of Directors at its meeting held today i.e. 19th May, 2023, has, inter alia fixed 10th August, 2023 as the record date for the payment of final dividend and 18th August, 2023 as the Cut-off date for the purpose of the Annual General Meeting. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2023. Kindly take the same on record. The Board of Directors at its meeting held today i.e. 19th May, 2023, has, inter alia, approved the alteration of Articles of Association ('AOA') of the Company, subject to the approval of the shareholders at the ensuing Annual General Meeting, to include Dhananjay and Madhurima Singh Trust as a member of Shareholders' Group II and to update the list of members in Shareholders' Group I and Shareholders' Group II to reflect the changes in the constituents thereof since the date of the Amended and Restated Shareholders Agreement dated 29th March, 2017. Kindly take the same on record. (As Per BSE Announcement dated on 19.05.2023)
24-Jan-2023	10-Feb-2023	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve (i) the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2022; and (ii) Interim Dividend for the financial year 2022-2023. The record date for the purpose of payment of Interim Dividend for the financial year 2022-2023 would be Saturday 18th February 2023 subject to declaration of the said Interim Dividend by the Board of Directors in its meeting to be held on 10th February 2023. The Board of Directors of the Company, at its meeting held today, i.e. 10th February, 2023 have inter alia: a. Approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2022. b. Declared Total Interim Dividend of Rs. 40/- (Rupees Forty only) per equity share on the face value of Rs. 2/- per share for the financial year 2022-23, including (i) Special Dividend of Rs. 25/- (Rupees Twenty-Five only) per equity share having a face value of Rs. 2/- per share; and (ii) Interim Dividend of Rs. 15/- (Rupees Fifteen only) per equity share having a face value of Rs. 2/- per share. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.10 p.m. Kindly take the same on record. In continuation of our letter dated 24th January, 2023 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting held today, i.e. 10th February, 2023 have inter alia approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2022. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Reg 33 of the Listing Regulations, is enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.00 a.m. and concluded at 01.10 p.m. Kindly take the same on record. (As Per BSE Announcement Dated on 10.02.2023)
02-Nov-2022	11-Nov-2022	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2022. Kindly take note of the same. The Board of Directors at its meeting held today i.e. 11.11.2022 has, inter alia: 1. approved the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30.09.2022. 2. based on recommendation of the NRC, Audit Committee and subject to the approval of shareholders, approved the re-appointment of Mr. Mritunjay Kumar Singh as an Executive Director of the Company for the term of 5 consecutive years w.e.f. 01.01.2023 upto 31.12.2027. Accordingly, we are enclosing herewith Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30.09.2022 alongwith the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.15 P.M. Kindly take the same on record. (As Per BSE Announcement dated on 11.11.2022)
14-Sep-2022	14-Sep-2022	Change in Directors	We wish to inform you that the Board of Directors ('Board') of Alkem Laboratories Limited (the 'Company'), at its meeting held today, i.e. on 14th September, 2022 has appointed Mr. Srinivas Singh (DIN: 06744441) as an Additional Director and Whole Time Director designated as an Executive Director on the Board of Directors of the Company for a period of five (5) consecutive years, with effect from 14th September, 2022 upto 13th September, 2027, subject to the approval of the shareholders of the Company. Necessary particulars in relation to the said appointment, are included in Annexure I. We also confirm that Mr. Srinivas Singh is not debarred from holding office of director by virtue of any SEBI order or any other such authority. This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors at its meeting held today i.e. 14th September, 2022 has decided to seek approval of the shareholders by way of postal ballot (voting by electronic means) for (a) appointment of Mr. Srinivas Singh (DIN: 06744441) as a Whole Time Director to be designated as an Executive Director for a period of five (5) consecutive years w.e.f 14th September, 2022 to 13th September, 2027 and (b) appointment of Mr. Sarandhar Singh- Vice President- Marketing and Sales to office/ place of profit in the Company. The Company has fixed 23rd September, 2022 as cut-off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and voting through electronic means.
25-Jul-2022	05-Aug-2022	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June 2022. Kindly take note of the same. The Board of Directors of the Company, at its meeting held today, i.e. 05.08.2022 have inter alia: 1. approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30.06 2022. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Reg 33 of the Listing Regulations, is enclosed herewith. 2. based on recommendation of Nomination and Remuneration Committee and subject to approval of shareholders, approved the appointment of Mr. Sujjain Talwar (DIN: 01756539) as an Additional Director designated as an Independent Director on the Board of Directors of the Company for a period of five (5) consecutive years with effect from 05.08.2022 to 04.08.2027. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.20 P.M. Kindly take the same on record. In continuation of our letter dated 25th July, 2022 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company, at its meeting held today, i.e. 05th August, 2022 have inter alia approved the Standalone and Consolidated Unaudited Financial Results for the quarter ended 30th June, 2022. A copy of the said Financial Results and Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations, is enclosed herewith. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.20 P.M. KIndly take the same on record. The Board of Directors at its meeting held today, i.e. 05th August, 2022, based on the recommendation of Nomination & Remuneration Committee and subject to approval of shareholders, approved the appointment of Mr. Sujjain Talwar (DIN: 01756539) as an Additional Director, designated as an Independent Director on the Board of Directors of the Company for a period of five (5) consecutive years with effect from 05th August, 2022 upto 04th August, 2027. Necessary particulars in relation to the said appointment, are included in Annexure I. We also confirm that Mr. Sujjain Talwar is not debarred from holding office of director by virtue of any SEBI order or any other such authority. Kindly take the same on your records. This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors of the Company at its meeting held today i.e. 05th August, 2022 have decided to seek approval of the shareholders by way of Postal Ballot through remote e-voting for appointment of Mr. Sujjain Talwar (DIN: 01756539) as an Independent Director of the Company to hold office for a period of five (5) consecutive years w.e.f. 05th August, 2022 to 04th August, 2027. The Company has fixed Friday, 19th August, 2022 as cut-off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and remote voting through electronic means. Kindly take note of the same. (As per BSE Announcement Dated on 05/08/2022)
28-Apr-2022	13-May-2022	Accounts	Audited Results & Final Dividend Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2022 ,inter alia, to consider and approve (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2022; and (ii) to consider and recommend Final Dividend, if any, for the Financial Year ended 31st March, 2022. Kindly take note of the same. The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia: 1. recommended a final dividend of Rs. 4/- per equity share of Rs. 2/- each for the financial year ended 31st March, 2022, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 48th Annual General Meeting of the Company shall be held on 25th August, 2022 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2022. 3. fixed 10th August, 2022 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record. Please find enclosed the outcome of the BM dated 13.5.22 In continuation of our letter dated 28th April, 2022 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (''Listing Regulations'') the Board of Directors of the Company, at its meeting held today, i.e. 13th May, 2022, has inter alia approved the Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2022. Accordingly, we are enclosing herewith Standalone and Consolidated Audited Financial Results for the quarter and financial year ended 31st March, 2022 and the Auditor''s Report thereon. The Company hereby declares that the Auditors have expressed an unmodified opinion in the Audit Reports on Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2022. The meeting of the Board of Directors of the Company commenced at 11.00 A.M and concluded at 1.30 P.M. Kindly take the same on record. Approved the appointment of M/s RSM & Co., Company Secretaries, as Secretarial Auditor of the Company for the financial year 2022-23. The Board of Directors at its meeting held today i.e. 13th May, 2022, has, inter alia: 1. recommended a final dividend of Rs. 4/- per equity share of Rs. 2/- each for the financial year ended 31st March, 2022, for the approval of the shareholders of the Company at the ensuing Annual General Meeting. 2. fixed that the 48th Annual General Meeting of the Company shall be held on 25th August, 2022 and the cut-off date for the purpose of the said Annual General Meeting has been fixed as 18th August, 2022. 3. fixed 10th August, 2022 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 30th August, 2022. Kindly take the same on record. (As Per BSE Announcement Dated on 13.05.2022)
24-Jan-2022	04-Feb-2022	Quarterly Results	Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2022 inter alia to consider and approve (i) the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2021; and (ii) Interim Dividend for the Financial Year 2021-2022. The record date for the purpose of payment of Interim Dividend for the Financial Year 2021-2022 would be Saturday 12th February 2022 subject to declaration of the said Interim Dividend by the Board of Directors in its meeting to be held on 04th February 2022. Kindly take note of the same. The Board of Directors of the Company, at its meeting held today, i.e. 04th February, 2022 have inter alia: a. Approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31st December, 2021. b. Declared Interim Dividend of Rs 30/- (Rupees Thirty only) per equity share on the face value of Rs. 2/- per share for the financial year 2021-22 pursuant to Regulation 43 read with Regulation 30 of the Listing Regulations. The meeting of the Board of Directors of the Company commenced at 10.30 a.m. and concluded at 01.00 p.m. Kindly take the same on record. (As Per BSE Announcement Dated on 04.02.2022)
20-Dec-2021	20-Dec-2021	Change in Directors	We wish to inform you that the Board of Directors ('Board') of Alkem Laboratories Limited (the 'Company'), at its meeting held today, i.e. on 20th December, 2021 has appointed Mrs. Madhurima Singh (DIN: 09137323) as an Additional Director and Whole Time Director designated as Executive Director on the Board for a period of five years, with effect from 20th December, 2021, subject to the approval of the shareholders of the Company. Necessary particulars in relation to the said appointment, are included in Annexure I. Kindly take the same on your records. This is to inform you that pursuant to the provisions of Section 110 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Board of Directors at its meeting held today i.e. 20th December, 2021 has decided to seek approval of the shareholders by way of postal ballot (voting by electronic means) for appointment of Mrs. Madhurima Singh (DIN: 09137323) as a Whole Time Director designated as Executive Director for a period of five consecutive years w.e.f 20th December, 2021. The Company has fixed 31st December, 2021 as cut-off date for ascertaining the eligibility of shareholders for dispatch of Postal Ballot Notice and voting through electronic means. Kindly take note of the same.

1 2

LOGIN HERE

Alkem Laboratories Ltd

Board Meeting